{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:26:55Z","timestamp":1768004815072,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Communicating information about the risks and benefits of benzodiazepines so that it is meaningful to the patient has not been previously described. This study aims to determine patient preferences regarding information received before initiating a benzodiazepine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An online survey was distributed through social media and advertisements to Canadians \u226518 years old over a 6\u2010month period (May\u2013Oct 2022) to collect participant's rating of importance of statements and factors about the risk and benefits of benzodiazepines before initiating treatment using a 10\u2010point Likert\u2010type scale. Treatment preferences based on efficacy and risk information were also elicited. The survey was developed and pilot\u2010tested in collaboration with an advisory committee of individuals with lived and living experience with benzodiazepine use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010seven participants responded to the survey (mean age 30 years old, 81.1% identified as female). The majority of respondents had a history of anxiety (83.8%) or insomnia (32.4%), and 10 (27.0%) respondents had used a benzodiazepine. Patient counseling related to withdrawal symptoms of benzodiazepines, risk of harm in combination with other sedating agents, risk of physical and psychological dependence, and risk of effects on cognition were rated high in the importance of receiving this information before starting a benzodiazepine relative to efficacy endpoints, such as improvement in sleep parameters. When provided with information about the chance of efficacy and risk of harm, 100% would have selected cognitive behavioral therapy as the best treatment option. The most frequently reported source of medication information where patients have sought information was from the internet (25.0%), followed by doctors (21.9%) and pharmacists (18.8%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study identified patient important factors and statements viewed as important to communicate before initiating a benzodiazepine. The findings of this survey study will help inform decision\u2010making when considering treatment options for managing anxiety or insomnia.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hsr2.1597","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T16:57:50Z","timestamp":1701449870000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient values and preferences regarding communicating risk versus benefit of benzodiazepine initiation: A cross\u2010sectional survey study"],"prefix":"10.1002","volume":"6","author":[{"given":"Karn","family":"Chahal","sequence":"first","affiliation":[{"name":"College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Glass","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Falk","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Singer","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0033-6877","authenticated-orcid":false,"given":"Christine","family":"Leong","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada"},{"name":"Department of Psychiatry, Max Rady College of Medicine, Rady Faculty of Health Sciences University of Manitoba Winnipeg Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,12]]},"reference":[{"key":"e_1_2_12_2_1","first-page":"213","article-title":"Use of prescription and nonprescription hypnotics in a Canadian elderly population","volume":"8","author":"Busto UE","year":"2001","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0714980810000115"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0579.2003.00212.x"},{"key":"e_1_2_12_5_1","unstructured":"Canadian Centre on Substance Abuse. Prescription sedatives (Canadian drug summary) 2015. p.1\u20106. Accessed November 3 2020.http:\/\/www.ccsa.ca\/Resource: Library\/CCSA\u2010Canadian\u2010Drug\u2010Summary\u2010Prescription\u2010Sedatives\u20102015\u2010en.pdf"},{"key":"e_1_2_12_6_1","unstructured":"CADTH.Discontinuation strategies for patients with long\u2010term benzodiazepine use: a review of clinical evidence and guidelines. Vol.1 Rapid Response Report: Summary with Critical Appraisal.2015. p.1\u201028. Accessed November 3 2020.http:\/\/www-ncbi-nlm-nih-gov.uml.idm.oclc.org\/pubmedhealth\/PMH0078914\/pdf\/PubMedHealth_PMH0078914.pdf"},{"key":"e_1_2_12_7_1","unstructured":"Canadian Centre on Substance Abuse. Effective interventions to manage symptoms of benzodiazepine withdrawal in seniors.2014. p.1\u20109. Accessed November 3 2020.http:\/\/www.ccsa.ca\/ResourceLibrary\/CCSA-Benzodiazepine-Withdrawal-Seniors-Rapid-Review-2014-en.pdf"},{"key":"e_1_2_12_8_1","first-page":"72","article-title":"Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian study of health and aging","volume":"10","author":"Hogan DB","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.1763"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1121189X00000531"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201500380"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.5867\/medwave.2018.01.7159"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/0023210-200923010-00002"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.925444"},{"issue":"12","key":"e_1_2_12_15_1","first-page":"1317","article-title":"Cognitive\u2010behavioural treatment for benzodiazepine dependence: a comparison of gradual versus abrupt cessation of drug intake","volume":"82","author":"Sanchez\u2010craig M","year":"1987","journal-title":"Addiction"},{"issue":"4","key":"e_1_2_12_16_1","first-page":"171","article-title":"The discontinuation of lorazepam and diazepam following sub\u2010chronic therapy in anxious outpatients","volume":"6","author":"Peperkamp P","year":"1993","journal-title":"J Drug Dev"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0907"},{"key":"e_1_2_12_18_1","unstructured":"Government of Manitoba.The Pharmaceutical Act. 2023. Accessed September 23 2023.https:\/\/web2.gov.mb.ca\/laws\/statutes\/ccsm\/p060.php"},{"key":"e_1_2_12_19_1","unstructured":"The College of Physicians and Surgeons of Manitoba. Standard of Practice: prescribing benzodiazepines and Z\u2010drugs (including zopiclone and other drugs). Effective date: November 1 2020. 2020. Accessed November 3 2020.https:\/\/cpsm.mb.ca\/laws-and-policies\/standards-of-practice-of-medicine"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3996"},{"key":"e_1_2_12_21_1","unstructured":"LeongC.Community engagement meeting College of Pharmacy University of Manitoba November 14 2018.2018."},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0106-8"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2893"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.949"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.134650"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-13-S2-S8"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.24.100901.141005"},{"key":"e_1_2_12_28_1","unstructured":"Deprescribing Network.Patient handouts.2020. Accessed November 20 2020.https:\/\/www.deprescribingnetwork.ca\/patient-handouts"},{"key":"e_1_2_12_29_1","unstructured":"RxFiles. Questions about anxiety and the answers that may surprise you. Accessed November 20 2020.https:\/\/www.rxfiles.ca\/RxFiles\/modules\/miscellaneous\/search.aspx?for=anxiety+"},{"key":"e_1_2_12_30_1","first-page":"79","volume-title":"Designing clinical research: an epidemiologic approach","author":"Hulley SB","year":"2013"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/20451253221082386"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph181910222"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.116"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.1597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:58:00Z","timestamp":1704934680000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.1597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1002\/hsr2.1597"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.1597","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"2023-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1597"}}